Insmed opens an office in Utrecht, Netherlands, further expanding its presence to Europe.
2016
Insmed enters into a worldwide license agreement with AstraZeneca for a product candidate, expanding the company’s rare disease pipeline.
2017
Insmed establishes a subsidiary in Japan.
2018
Insmed submits a New Drug Application to the FDA for its lead product candidate.
2018
Insmed is granted accelerated approval by the FDA for its first therapy.
2019
Insmed opens its new, state-of-the-art global headquarters in Bridgewater, NJ, to support the Company’s continued growth.